Pyxis Oncology Inc
Pyxis Oncology Inc (PYXS) Option Chain
As of September 21, 2026, Pyxis Oncology Inc is trading at $3.19, a -4.21% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 147.7%. IV Rank is 22%.
Read more
Tracking the PYXS option chain helps you see every strike and expiry on Pyxis Oncology Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Pyxis Oncology Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of PYXS options activity at a glance. Use our scanner to monitor the PYXS option chain in real time and filter for the PYXS options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For PYXS stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the PYXS option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where PYXS stock options are being actively traded and where they are not.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Pyxis Oncology Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen PYXS options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of PYXS stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile28.17% Subdued
- Market cap (M$)266
- 52 weeks high-42.52%
- 52 weeks low209.71%
- Analyst recommendationStrong Buy
1.20 - Target price$8.44
164.58% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-02
- P/E—
- Future P/E—
- EPS (ttm)-1.40
- EPS growth next 5 years4.96%
As of September 21, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 0.23 | 25 | 0 | 0.21 | 2.19 | 2.05 | 2.75 | 1.00 | -68.65 | — | 0.05 | 0.00 | 0.05 | 0 | 2 | 99.77 |
| 3.76 | 135 | 0 | 0.24 | 1.69 | 1.55 | 2.30 | 1.50 | -52.98 | — | 0.75 | 0.00 | 0.75 | 0 | 0 | 96.24 |
| 15.14 | 6 | 0 | 0.29 | 1.19 | 1.00 | 1.95 | 2.00 | -37.30 | — | 0.10 | 0.00 | 0.10 | 0 | 54 | 84.86 |
| 32.66 | 361 | 1 | 0.16 | 0.69 | 0.60 | 1.10 | 2.50 | -21.63 | — | 0.15 | 0.00 | 0.15 | 7 | 195 | 67.34 |
| 91.23 | 3,552 | 32 | 0.13 | 0.00 | 0.10 | 0.15 | 5.00 | +56.74 | 1.25 | 2.25 | 1.81 | -0.06 | 0 | 127 | 8.77 |
As of September 21, 2026
Scan the full option chain in one place
Browse the full PYXS option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→